MX2021004709A - Metodo y medicamento para tratar cancer insensible a inhibidor de se?alizacion de pd-1/pd-l1. - Google Patents

Metodo y medicamento para tratar cancer insensible a inhibidor de se?alizacion de pd-1/pd-l1.

Info

Publication number
MX2021004709A
MX2021004709A MX2021004709A MX2021004709A MX2021004709A MX 2021004709 A MX2021004709 A MX 2021004709A MX 2021004709 A MX2021004709 A MX 2021004709A MX 2021004709 A MX2021004709 A MX 2021004709A MX 2021004709 A MX2021004709 A MX 2021004709A
Authority
MX
Mexico
Prior art keywords
treating cancer
signaling inhibitor
medicament
cancer unresponsive
unresponsive
Prior art date
Application number
MX2021004709A
Other languages
English (en)
Inventor
Nobuyuki Ishikura
Toshiki Iwai
Masamichi Sugimoto
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2021004709A publication Critical patent/MX2021004709A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Abstract

La presente invención se refiere a medicamentos, métodos de tratamiento, kits y usos para tratar el cáncer en individuos, caracterizados porque un inhibidor de señalización de VEGF y un inhibidor de señalización de PD-1/PD-L1 se administran en combinación, así como a inhibidores de señalización de VEGF, inhibidores de señalización de PD-1/PD-L1 y combinaciones de estos.
MX2021004709A 2018-10-31 2019-10-17 Metodo y medicamento para tratar cancer insensible a inhibidor de se?alizacion de pd-1/pd-l1. MX2021004709A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018206076 2018-10-31
PCT/IB2019/058848 WO2020089722A1 (en) 2018-10-31 2019-10-17 Method and medicament for treating cancer unresponsive to pd-1/pd-l1 signaling inhibitor

Publications (1)

Publication Number Publication Date
MX2021004709A true MX2021004709A (es) 2021-06-04

Family

ID=70463563

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004709A MX2021004709A (es) 2018-10-31 2019-10-17 Metodo y medicamento para tratar cancer insensible a inhibidor de se?alizacion de pd-1/pd-l1.

Country Status (12)

Country Link
US (1) US20210388090A1 (es)
EP (1) EP3873527A4 (es)
JP (1) JP2022509448A (es)
KR (1) KR20210084560A (es)
CN (1) CN114340679A (es)
AU (1) AU2019372239A1 (es)
BR (1) BR112021008117A2 (es)
CA (1) CA3115798A1 (es)
IL (1) IL282654A (es)
MX (1) MX2021004709A (es)
TW (1) TW202031291A (es)
WO (1) WO2020089722A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106397592A (zh) * 2015-07-31 2017-02-15 苏州康宁杰瑞生物科技有限公司 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
WO2022089377A1 (en) * 2020-10-26 2022-05-05 Taizhou Eoc Pharma Co., Ltd. Combination of a pd-1 or pd-l1 antagonist and a vegfr inhibitor for treating cancer
WO2023088436A1 (zh) * 2021-11-18 2023-05-25 信达生物制药(苏州)有限公司 抗pd-1抗体和抗vegf-a抗体的药物组合及其使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3971209A1 (en) * 2014-02-04 2022-03-23 Pfizer Inc. Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
MX2017016324A (es) * 2015-06-16 2018-03-02 Merck Patent Gmbh Tratamientos de combinacion de antagonista de ligando 1 de muerte programada (pd-l1).
US10544224B2 (en) * 2015-07-14 2020-01-28 Bristol-Myers Squibb Company Method of treating cancer using immune checkpoint inhibitor
TW201837467A (zh) * 2017-03-01 2018-10-16 美商建南德克公司 用於癌症之診斷及治療方法

Also Published As

Publication number Publication date
JP2022509448A (ja) 2022-01-20
BR112021008117A2 (pt) 2021-08-31
CN114340679A (zh) 2022-04-12
WO2020089722A1 (en) 2020-05-07
TW202031291A (zh) 2020-09-01
AU2019372239A1 (en) 2021-05-20
EP3873527A1 (en) 2021-09-08
US20210388090A1 (en) 2021-12-16
IL282654A (en) 2021-06-30
EP3873527A4 (en) 2022-09-07
KR20210084560A (ko) 2021-07-07
CA3115798A1 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
MX2022001757A (es) Inhibidores de muerte programada 1 (pd-19)/ligando de muerte programada 1 (pd-l1) para el tratamiento de cancer.
MX2018014435A (es) Inhibidores de muerte programada 1 (pd-1) ligando de muerte programada (pd-l1) para el tratamiento de cancer.
PH12021500004A1 (en) Pd-1/pd-l1 inhibitors
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
PH12017501818A1 (en) Fgfr/pd-1 combination therapy for the treatment of cancer
CR20190478A (es) Inhibidores de pd-1/pd-l1
MX2018016046A (es) Quinazolina y compuestos indol para tratar trastornos medicos.
BR112018073328A2 (pt) combinação, composição farmacêutica, kit, método para tratamento de câncer, método para a redução de um nível de células, método para reduzir o nível de células, método para aumentar a atividade, método para aumentar a citotoxicidade
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
SG10201811128RA (en) Ezh2 inhibitors for treating lymphoma
MX2021004709A (es) Metodo y medicamento para tratar cancer insensible a inhibidor de se?alizacion de pd-1/pd-l1.
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
MX2020013808A (es) Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer.
WO2019090347A8 (en) Adenosine pathway inhibitors for cancer treatment
AU2017277478A1 (en) Pharmaceutical combinations for treating cancer
MX2019013862A (es) Terapia de combinacion.
AU2015267099A8 (en) Use of eribulin in the treatment of cancer
MX2017009246A (es) Farmaco de combinacion.
MX2017011018A (es) Inhibicion de la actividad de olig2.
ZA201901367B (en) Inhibition of olig2 activity
MX2020003361A (es) Combinacion de un inhibidor parp y un antagonista de union al eje pd-1.
MX2020006224A (es) Metodos y terapia combinada para el tratamiento del cancer.
MX2021006915A (es) Inhibidores de cxcr7 para el tratamiento de cancer.
MX2021002818A (es) Métodos para tratar el cáncer mediante la inhibición de la enzima conjugadora de ubiquitina e2 k (ube2k).
MX2019005194A (es) Combinaciones de inhibidores de fgfr4 y secuestrantes de acido biliar.